The Bank of London Formally Applies for European Union Banking Licence and Announces 200M Euros Investment and 300 New Jobs in Luxembourg
The Bank of London today announces it has submitted its formal application for a European Union (EU) Banking Licence and commits to 200M euros investment and hiring 300 people in Luxembourg over the next five years.
The formal application has been jointly lodged with the European Central Bank and Commission de Surveillance du Secteur Financier (CSSF) in Luxembourg.
Formally establishing a base in the EU enables The Bank of London to support businesses in the world’s largest single market and trading bloc. The 200M euros investment in Luxembourg and across the wider EU will help power the bank’s EU growth and the creation of 300 new jobs including management, compliance, risk, product development and business control, technology and operations.
Commenting on The Bank of London’s choice of Luxembourg, Head of Luxembourg for Finance, Nicolas Mackel, said: “The choice by The Bank of London is an enrichment for Luxembourg's financial services ecosystem and testimony to its attractiveness for such a technology-based operator.”
Guy Hoffman, Chairman of The Bankers' Association in Luxembourg, said: “Luxembourg’s digital technology programme was specifically set up to help businesses and consumers and the potential for The Bank of London’s unique offering is enormous.”
The Bank of London, powered by its patented technologies, has a unique business model that actively protects its depositors’ funds by never lending, leveraging or investing these deposits. By choosing Luxembourg as its EU headquarters, there is an exciting opportunity to offer Luxembourg and the broader EU market a new global digital clearing ecosystem for financial institutions and corporate commercial clients.
Norbert Becker, Chairperson of the European Union region for The Bank of London, said: “This is a major milestone for our business and follows the foundation established in the UK. Luxembourg is perfectly positioned to play a key role in driving the bank’s European business forward, and ensuring Luxembourg is the centre of clearing for the EU.”
Anthony Watson, Group Chief Executive & Founder of The Bank of London, said: “Luxembourg is the logical choice for us to build out our offering across the EU, and marks the latest step in our international growth strategy and follows the successful rollout of our banking solutions across the UK.”
The Bank of London boasts Luxembourg-based Mangrove Capital Partners as one of its key shareholders.
For more information visit: thebankoflondon.com, or on Twitter and Instagram at: @thebankoflondon.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712289844/en/
Contact information
Enquiries:
The Bank of London
Gavin Haycock
Gavin.haycock@thebankoflondon.com
+44(0) 7557 038031
Powerscourt
Siobhan McCluskey
Siobhan.McCluskey@powerscourt-group.com
+44(0) 7795 611179
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services, PALFINGER Inaugurate GDC as Part of Multi-Year Engagement to Accelerate Product Development10.12.2025 09:30:00 EET | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced the inauguration of a state-of-the-art Global Development Center - APAC as part of a multi-year engagement with PALFINGER, an Austria-headquartered global pioneer in innovative crane and lifting solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209416315/en/ From PALFINGER, the ceremony was attended by Alexander Susanek (COO), Andreas Hille (Senior Vice President, Product Line Management and Engineering), Santhosh Rao (Senior Vice President Regional Sales & Service, Asia Pacific) and Arun C Bhongale (General Manager, SCM and Procurement). From LTTS, Mritunjay Singh (COO), Dr. Oliver Moron (Vice President, EU-DACH), Mohideen Farouk (Sales Director, EU-DACH), Jayant Joshi (Delivery Head, T&OH), Tejas B Shah (Delivery Head, Agriculture & Material Handling) and Sachin Nikam (Delivery Manager) we
New Study Reveals Surging Consumer Demand for Seamless Car-to-Home Audio10.12.2025 09:10:00 EET | Press release
Over 9 in 10 consumers say they are likely to seek out audio devices that allow smooth movement between car and home, according to a consumer survey conducted by Futuresource Consulting on behalf of Cinemo, a leading provider of in-car infotainment solutions and the company behind the first open cloud ecosystem connecting audio devices, content, and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209006640/en/ "From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience" Survey conducted by Futuresource Consulting on behalf of Cinemo; November 2025 The report, “From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience”, drawn from more than 500 connected device users in China, where smart home and in-car connectivity adoption is among the highest globally, focused on four core themes: How consumers use audio across both home and in-car environments Their expect
Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 08:01:00 EET | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual
NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 06:00:00 EET | Press release
NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 04:50:00 EET | Press release
Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
